Location Directory

Clinical trials in Birmingham, Alabama

This page shows live ClinicalTrials.gov search results for Birmingham, Alabama, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

9516

Shown on this page

Current sort

Institutions in Birmingham

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

University of Alabama at Birmingham

Live official records

Open in full search

Conditions: Obesity, Type 2 Diabetes
Interventions: Cagrisema, Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 99
States / cities: Birmingham, Alabama • Pelham, Alabama • Gilbert, Arizona + 81 more

Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Interventions: volrustomig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 69
States / cities: Birmingham, Alabama • Phoenix, Arizona • Prescott Valley, Arizona + 61 more

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Pumitamig, Durvalumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 38
States / cities: Daphne, Alabama • Golden, Colorado • Newark, Delaware + 32 more

Conditions: Obesity
Interventions: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 3,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 46
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 35 more

Conditions: Kidney Disease
Interventions: Mezagitamab, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 41
States / cities: Birmingham, Alabama • Montgomery, Alabama • Surprise, Arizona + 35 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: BMS-986365, Enzalutamide, Abiraterone, Docetaxel, Predinsone/Prednisolone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 48
States / cities: Birmingham, Alabama • Gilbert, Arizona • Anaheim, California + 34 more

Conditions: Diabetes Mellitus, Overweight, Obesity
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • Escondido, California • Lomita, California + 12 more

Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer
Interventions: Nivolumab, Sitravatinib, Docetaxel; Biological · Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 133
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 109 more

Conditions: Asthma
Interventions: FF/UMEC/VI, ELLIPTA, FF/VI; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 28
States / cities: Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 23 more

Conditions: HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
Interventions: ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138; Drug
Lead sponsor: QuantumLeap Healthcare Collaborative; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more

Conditions: Dyspareunia
Interventions: Estradiol, Imvexxy, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 1,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 42
States / cities: Birmingham, Alabama • Chandler, Arizona • Sacramento, California + 36 more

Conditions: Locally Advanced Cervical Cancer
Interventions: Volrustomig, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 15 Years and older · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 24 more

Clinical trials in Birmingham, Alabama

Filter and sort this location

Institutions in Birmingham

Live official records

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

PRE-ISPY Phase I/II Oncology Platform Program

Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)